July 2018
Volume 59, Issue 9
ARVO Annual Meeting Abstract  |   July 2018
Laser versus Bevacizumab for Type-1 Retinopathy of Prematurity: FA vs OCT-A at 4 years of age
Author Affiliations & Notes
  • Domenico Lepore
    Dept of Ophthalmology, Catholic University, Rome, Italy
  • Lorenzo Orazi
    IAPB ITALIA onlus , Italian National Center of services and Research for Prevention of Blindness and Rehabilitation of the Visually impaired, Rome, Italy
  • Marco H. Ji
    Dept of Ophthalmology, Catholic University, Rome, Italy
  • Giulia Maria Amorelli
    Dept of Ophthalmology, Catholic University, Rome, Italy
  • Fernando Molle
    Dept of Ophthalmology, Catholic University, Rome, Italy
  • Graham E Quinn
    Division of Pediatric Ophthalmology, , The Children’s Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, , Philadelphia, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   Domenico Lepore, None; Lorenzo Orazi, None; Marco Ji, None; Giulia Maria Amorelli, None; Fernando Molle, None; Graham Quinn, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3755. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Domenico Lepore, Lorenzo Orazi, Marco H. Ji, Giulia Maria Amorelli, Fernando Molle, Graham E Quinn; Laser versus Bevacizumab for Type-1 Retinopathy of Prematurity: FA vs OCT-A at 4 years of age. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3755. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To study long term FA and OCT-A findings in a single center randomized study aimed to compared traditional laser treatment for Type 1 retinopathy of prematurity (ROP) with intravitreal injection of bevacizumab in the fellow eye.

Methods : Twenty-one inborn babies with type 1 zone 1 ROP were included in the study. One eye was randomized to receive an intravitreal injection of 0.5mg bevacizumab; the fellow eye received conventional laser photoablation. Fluorescein angiography, OCT and OCT-A images from 6 subjects (12 eyes) were obtained 4 years after treatment.
Fluorescein angiographic findings were classified as previously described. OCT and OCT-A foveal structure was analysed and differences calculated in pixels with ImageJ software.

Results : FA demonstrated a well-defined foveal avascular zone in all 12 eyes. All bevacizumab-treated eyes showed avascular peripheral retina with vascular abnormalities. On OCT in all subjects, bevacizumab-treated eyes tended to have thinner fovea than laser-treated eyes; OCT-A showed in all eyes a persistent superficial capillary network in the foveal region.

Conclusions : different imaging techniques are complementary in this study. Further studies are need to understand different aspects of the developing foveal structure.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.